CNS Pharmacology: Antiepileptic Drugs

Introduction / Overview

Epilepsy represents a heterogeneous group of neurological disorders characterized by recurrent seizures of varying etiology, frequency, and severity. Antiepileptic drugs (AEDs) constitute the cornerstone of therapeutic management for most patients, aiming to suppress epileptogenic neuronal activity while minimizing adverse effects. The clinical relevance of AEDs is underscored by their broad application across diverse seizure types, including partial, generalized, and refractory epilepsy. A nuanced understanding of AED pharmacology is essential for optimized patient care, particularly in the context of polypharmacy, comorbidities, and evolving therapeutic options.

• To delineate the principal pharmacologic classes of AEDs and their chemical foundations.
• To elucidate the mechanisms of action, including receptor interactions and cellular effects.
• To describe key pharmacokinetic parameters that influence dosing strategies.
• To outline approved therapeutic indications and common off‑label uses.
• To review adverse effect profiles, serious risks, and drug‑interaction potentials.
• To address special considerations in pregnancy, lactation, pediatrics, geriatrics, and organ impairment.

Classification

Drug Classes and Categories

AEDs are traditionally categorized based on their primary pharmacologic target or mechanism of action. The following major classes are commonly referenced:

• Voltage‑gated sodium channel blockers (e.g., phenytoin, carbamazepine, lamotrigine, oxcarbazepine, lacosamide).
• GABA‑ergic enhancers (e.g., phenobarbital, benzodiazepines, vigabatrin, tiagabine, clonazepam).
• Potassium channel modulators (e.g., retigabine, lacosamide).
• T‑type calcium channel blockers (e.g., ethosuximide, trimethadione).
• AMPA/KAR antagonists (e.g., perampanel).
• Novel agents with unique mechanisms (e.g., levetiracetam, brivaracetam, rufinamide, eslicarbazepine, stiripentol).

Chemical Classification

From a chemical standpoint, AEDs can be grouped into distinct families based on structural motifs:

• Phenols (e.g., phenytoin, phenobarbital).
• Benzodiazepines (e.g., diazepam, clonazepam).
• Oxadiazoles (e.g., valproate). (Note: valproate is a divalproex ester.)
• Phenylalanine derivatives (e.g., levetiracetam).
• Carbamazepine analogues (e.g., oxcarbazepine, eslicarbazepine).
• Polyunsaturated fatty acid derivatives (e.g., fenfluramine, not currently approved).

Mechanism of Action

Voltage‑Gated Sodium Channel Blockers

These agents preferentially stabilize the inactivated state of voltage‑dependent sodium channels, thereby attenuating repetitive neuronal firing. The voltage‑dependent blockade is use‑dependent, with higher affinity for rapidly firing neurons. The degree of channel blockade correlates with therapeutic efficacy and seizure type specificity. For instance, lamotrigine exhibits preferential blockade of slowly inactivating sodium channels, rendering it effective in generalized tonic‑clonic and absence seizures.

GABA‑ergic Enhancers

Several AEDs augment inhibitory neurotransmission by enhancing GABAergic activity. Phenobarbital and benzodiazepines potentiate GABA_A receptor currents, prolonging chloride ion influx and hyperpolarizing the neuronal membrane. Vigabatrin irreversibly inhibits GABA transaminase, thereby increasing synaptic GABA concentrations. Tiagabine blocks GABA reuptake transporters, prolonging GABA availability in the synaptic cleft.

Potassium Channel Modulators

Agents such as retigabine open potassium channels, hyperpolarizing neuronal membranes and reducing excitability. Lacosamide, while primarily a sodium channel blocker, also potentiates slow inactivation of sodium channels and modulates potassium channels, contributing to its antiepileptic profile.

T‑Type Calcium Channel Blockers

Ethosuximide selectively inhibits low‑threshold T‑type calcium channels, thereby reducing thalamocortical rhythmic activity characteristic of absence seizures. Trimethadione shares a similar profile but is less frequently used due to its toxicity profile.

AMPA/KAR Antagonists

Perampanel non‑competitively blocks AMPA receptors, attenuating excitatory glutamatergic signaling. This mechanism is particularly advantageous in focal seizures with secondary generalization.

Novel Mechanisms

Levetiracetam binds to the synaptic vesicle protein SV2A, modulating neurotransmitter release. Brivaracetam shares the SV2A affinity but exhibits higher potency. Rufinamide, a unique compound, modulates voltage‑dependent sodium channel inactivation and exerts a preferential effect on burst firing. Stiripentol enhances GABAergic activity via potentiation of GABA_A receptors and inhibition of GABA transaminase, useful in Dravet syndrome.

Pharmacokinetics

Absorption

Oral bioavailability varies among AEDs. Phenytoin and carbamazepine are absorbed rapidly, with peak plasma concentrations (C_max) reached within 1–2 h. Valproate demonstrates high oral bioavailability (80–90 %), while levetiracetam achieves near‑complete absorption (>90 %). Food intake may influence absorption; for example, high‑fat meals can delay the onset of phenytoin absorption.

Distribution

Plasma protein binding ranges from low (e.g., levetiracetam, ~10 %) to high (e.g., phenytoin, ~90 %). The blood‑brain barrier penetration is generally favorable for most AEDs, but the extent varies. The volume of distribution (V_d) for valproate is approximately 10 L kg⁻¹, whereas phenytoin’s V_d is around 0.2–0.3 L kg⁻¹.

Metabolism

Hepatic metabolism predominates for many AEDs. Phenytoin undergoes saturable oxidation via CYP2C9 and CYP2C19; carbamazepine is metabolized by CYP3A4 to the active epoxide. Valproate undergoes glucuronidation and mitochondrial β‑oxidation; it is not primarily metabolized by CYP enzymes. Levetiracetam is largely excreted unchanged, with minimal hepatic metabolism. The metabolic pathways influence drug interactions and dose adjustments in hepatic impairment.

Excretion

Renal excretion is the main elimination route for levetiracetam, gabapentin, and pregabalin. Valproate and phenytoin are excreted via the bile and feces. Renal clearance is reduced in patients with impaired kidney function, necessitating dose modifications. For instance, levetiracetam clearance decreases by approximately 50 % in severe renal insufficiency.

Half‑Life and Dosing Considerations

• Phenytoin: 20–60 h, dosing adjusted for therapeutic drug monitoring due to non‑linear kinetics.
• Carbamazepine: 12–20 h, with dose titration to achieve therapeutic ranges.
• Valproate: 9–16 h, with therapeutic levels often targeted at 50–100 μg mL⁻¹.
• Levetiracetam: 7–12 h, convenient once‑daily dosing in many patients.
• Perampanel: 105 h, requiring gradual titration to mitigate dizziness and ataxia.

Therapeutic Uses / Clinical Applications

Approved Indications

Common indications include:

• Partial‑onset seizures (phenytoin, carbamazepine, levetiracetam).
• Generalized tonic‑clonic seizures (valproate, levetiracetam, carbamazepine).
• Absence seizures (ethosuximide, valproate).
• Myoclonic seizures (valproate, levetiracetam).
• Focal seizures with secondary generalization (perampanel, lacosamide).
• Refractory status epilepticus (benzodiazepines, intravenous phenytoin).

Off‑Label Uses

Off‑label applications are frequently encountered in clinical practice:

• Neuropsychiatric disorders (gabapentin for neuropathic pain, anxiety).
• Sleep disorders (eslicarbazepine for insomnia).
• Seizure prophylaxis in brain injury or post‑operative settings (levetiracetam, valproate).
• Management of epilepsy in patients with comorbid psychiatric conditions (clobazam, clonazepam).

Adverse Effects

Common Side Effects

• Valproate: weight gain, tremor, hair loss, nausea, and mild hepatotoxicity.
• Phenytoin: gingival hyperplasia, hirsutism, ataxia, and cerebellar signs.
• Carbamazepine: dizziness, diplopia, hyponatremia, rash.
• Phenobarbital: sedation, ataxia, cognitive slowing.
• Levetiracetam: dizziness, somnolence, irritability, mood changes.

Serious / Rare Adverse Reactions

• Valproate: severe hepatotoxicity, pancreatitis, thrombocytopenia, and teratogenic effects (neural tube defects).
• Phenytoin: Stevens‑Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug‑induced hypersensitivity syndrome.
• Carbamazepine: SJS/TEN, severe cutaneous reactions, aplastic anemia.
• Phenobarbital: respiratory depression, dependence, withdrawal syndrome.
• Valproate: hyperammonemia leading to encephalopathy.

Black Box Warnings

Valproate carries a black box warning regarding the risk of fetal malformations, including neural tube defects, when used during pregnancy. Phenobarbital and carbamazepine are also associated with teratogenic risks, particularly with neural tube defects and cleft lip/palate.

Drug Interactions

Major Drug‑Drug Interactions

• Phenytoin induces CYP3A4, potentially decreasing the efficacy of oral contraceptives and other CYP3A4 substrates.
• Carbamazepine similarly induces hepatic enzymes, reducing plasma levels of warfarin, cyclosporine, and antiretroviral agents.
• Valproate inhibits CYP2C9, CYP2C19, and CYP3A4, leading to increased concentrations of concomitant drugs metabolized by these pathways.
• Phenobarbital induces CYP2B6, CYP2C9, and CYP2C19, affecting the pharmacokinetics of numerous psychotropic medications.
• Levetiracetam has a low potential for drug interactions due to minimal CYP involvement.

Contraindications

Contraindications include:

• Known hypersensitivity to the drug or its excipients.
• Severe hepatic impairment (e.g., phenytoin, carbamazepine).
• Severe renal impairment for renally cleared AEDs (e.g., levetiracetam, gabapentin).
• Concurrent use of drugs that may synergistically depress the central nervous system (e.g., alcohol, benzodiazepines).

Special Considerations

Pregnancy / Lactation

Valproate carries a high teratogenic risk and is generally avoided during pregnancy unless alternative therapies are ineffective. Phenytoin and carbamazepine also pose teratogenic risks, particularly linked to neural tube defects and craniofacial anomalies. Phenobarbital and benzodiazepines may be used cautiously, with careful monitoring of fetal development. Lactation considerations emphasize drug excretion into breast milk; for instance, levetiracetam concentrations in milk are low, making it relatively safe.

Pediatric Considerations

Pediatric dosing requires weight‑based calculations and frequent therapeutic drug monitoring, particularly for phenytoin and carbamazepine. Growth and development are potential concerns with valproate, especially regarding neurocognitive outcomes. Newer AEDs such as levetiracetam and lacosamide have favorable safety profiles in children, yet monitoring for behavioral changes remains prudent.

Geriatric Considerations

Age‑related pharmacokinetic changes, including reduced hepatic metabolism and decreased renal clearance, necessitate dose adjustments in older adults. Sensitivity to central nervous system depressants increases the risk of falls and cognitive impairment. Polypharmacy heightens the potential for drug interactions.

Renal / Hepatic Impairment

• Renal impairment: Levetiracetam, gabapentin, and pregabalin require dose reductions proportional to creatinine clearance.
• Hepatic impairment: Phenytoin, carbamazepine, and valproate exhibit altered pharmacokinetics; careful monitoring and dose titration are advised. In severe hepatic dysfunction, alternative agents with minimal hepatic metabolism are preferred.

Summary / Key Points

• Antiepileptic drugs target diverse neuronal mechanisms, primarily sodium channel blockade, GABAergic potentiation, and modulation of calcium or potassium channels.
• Pharmacokinetic variability, including nonlinear metabolism and protein binding, underpins the necessity for therapeutic drug monitoring, particularly for phenytoin and carbamazepine.
• Common adverse effects vary by agent; serious reactions such as hepatotoxicity and severe cutaneous reactions warrant vigilance.
• Drug interactions are frequent due to enzyme induction or inhibition; careful medication reconciliation is essential in patients on polypharmacy.
• Special populations—including pregnant women, pediatric and geriatric patients, and those with organ impairment—require individualized dosing and monitoring strategies.

Clinical pearls include the preference for levetiracetam in patients with significant hepatic dysfunction, the necessity of folate supplementation when valproate is prescribed during pregnancy, and the importance of a gradual titration schedule to mitigate dizziness and ataxia with sodium channel blockers. Continual appraisal of emerging AEDs will further refine therapeutic algorithms and improve patient outcomes.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.